Intra-Cellular Therapies Stock Hits All-Time High of $131.47

In a remarkable display of market confidence, Intra-Cellular Therapies (NASDAQ:ITCI) stock has soared to an all-time high, reaching a price level of $131.47. According to InvestingPro data, the company boasts a market capitalization of nearly $14 billion and maintains strong liquidity with a current ratio of 6.36, though technical indicators suggest the stock may be entering overbought territory. This significant milestone underscores the biopharmaceutical company’s impressive performance over the past year, which has seen the stock’s value more than double with a 1-year change of 100.86%. Investors have rallied behind Intra-Cellular Therapies, buoyed by promising developments in its drug pipeline and strong financial results, including remarkable revenue growth of 46.62% in the last twelve months. The stock’s momentum has propelled it to unprecedented heights, setting a new benchmark for the company’s market valuation. Discover 15 additional key insights about ITCI with an InvestingPro subscription, including detailed valuation metrics and growth projections.

In other recent news, Intra-Cellular Therapies is progressing toward its merger with Johnson & Johnson, as the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act has expired. This merger, valued at approximately $14.6 billion, is subject to shareholder approval and other customary conditions, with a special meeting scheduled for March 27, 2025. Analyst firms have adjusted their ratings on Intra-Cellular Therapies, with Mizuho (NYSE:MFG), Canaccord Genuity, and RBC Capital all downgrading the stock while setting a price target of $132, aligning with the acquisition price. These downgrades reflect the expected alignment of the stock with the acquisition terms and the strategic fit within Johnson & Johnson’s portfolio. Johnson & Johnson’s acquisition strategy aims to strengthen its neuroscience franchise, with Intra-Cellular’s CAPLYTA potentially expanding its market reach. Meanwhile, S&P Global Ratings has placed Johnson & Johnson’s ’AAA’ credit rating on CreditWatch Negative, citing increased leverage due to the acquisition. The rating agency projects that Johnson & Johnson will reduce its leverage by the end of 2026, assuming continued business growth and smaller acquisitions. Investors are closely monitoring these developments, particularly the potential label expansion for CAPLYTA and the merger’s completion.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.